Dataset Information


Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.

ABSTRACT: Lung cancers with activating KRAS mutations are characterized by treatment resistance and poor prognosis. In particular, the basis for their resistance to radiation therapy is poorly understood. Here, we describe a radiation resistance phenotype conferred by a stem-like subpopulation characterized by mitosis-like condensed chromatin (MLCC), high CD133 expression, invasive potential, and tumor-initiating properties. Mechanistic investigations defined a pathway involving osteopontin and the EGFR in promoting this phenotype. Osteopontin/EGFR-dependent MLCC protected cells against radiation-induced DNA double-strand breaks and repressed putative negative regulators of stem-like properties, such as CRMP1 and BIM. The MLCC-positive phenotype defined a subset of KRAS-mutated lung cancers that were enriched for co-occurring genomic alterations in TP53 and CDKN2A. Our results illuminate the basis for the radiation resistance of KRAS-mutated lung cancers, with possible implications for prognostic and therapeutic strategies. Cancer Res; 77(8); 2018-28. ©2017 AACR.


PROVIDER: S-EPMC5445902 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC4652993 | BioStudies
2013-01-01 | S-EPMC3825323 | BioStudies
1000-01-01 | S-EPMC4051153 | BioStudies
2015-01-01 | S-EPMC4548796 | BioStudies
2013-01-01 | S-EPMC5217442 | BioStudies
2019-01-01 | S-EPMC6825300 | BioStudies
2020-01-01 | S-EPMC6980768 | BioStudies
2016-01-01 | S-EPMC4963474 | BioStudies
1000-01-01 | S-EPMC5352416 | BioStudies
2017-01-01 | S-EPMC5636688 | BioStudies